Levosimendan in Europe and China: An Appraisal of Evidence and Context
The calcium sensitiser levosimendan (SIMDAX; Orion Pharma) has been in clinical use for the management of acute heart failure and a range of related syndromes in many countries around the world for two decades. More recently, levosimendan has become available in China. The authors have examined the...
Main Authors: | Xiangqing Kong, Xinqun Hu, Baotong Hua, Francesco Fedele, Dimitrios Farmakis, Piero Pollesello |
---|---|
Format: | Article |
Language: | English |
Published: |
Radcliffe Medical Media
2021-11-01
|
Series: | European Cardiology Review |
Online Access: | https://www.ecrjournal.com/articleindex/ecr.2021.41 |
Similar Items
-
Levosimendan‐induced venodilation is mediated by opening of potassium channels
by: Daniel Burkhoff, et al.
Published: (2021-12-01) -
Haemodynamic Balance in Acute and Advanced Heart Failure: An Expert Perspective on the Role of Levosimendan
by: Piergiuseppe Agostoni, et al.
Published: (2019-11-01) -
Use of Levosimendan in Patients with Advanced Heart Failure: An Update
by: Daniele Masarone, et al.
Published: (2022-10-01) -
Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use
by: Zoltán Papp, et al.
Published: (2020-08-01) -
The levosimendan metabolite OR-1896 elicits vasodilation by activating the K(ATP) and BK(Ca) channels in rat isolated arterioles.
by: Erdei, N, et al.
Published: (2006)